Format

Send to

Choose Destination
J Am Coll Cardiol. 2018 Oct 2;72(14):1640-1652. doi: 10.1016/j.jacc.2018.07.049.

Artificial Lungs for Lung Failure: JACC Technology Corner.

Author information

1
Department of Biomedical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania.
2
Division of Cardiovascular Surgery, Lewis Katz School of Medicine, Temple University Health System, Philadelphia, Pennsylvania.
3
Division of Cardiovascular Surgery, Lewis Katz School of Medicine, Temple University Health System, Philadelphia, Pennsylvania. Electronic address: Norihisa.Shigemura@tuhs.temple.edu.

Abstract

Although lung transplantation is an effective treatment for end-stage lung failure, its limitations have led to renewed interest in artificial lung support for patients with lung failure. The use of ventricular assist devices has significantly improved the quality of life and survival of patients with end-stage heart failure. In contrast, there are no devices that can be used long term as destination therapy for end-stage lung failure, and there is a strong need for them. Extracorporeal membrane oxygenation is widely used as a temporary treatment for acute lung failure and as a bridge to lung transplant. Many patients with advanced lung failure cannot return home with good quality of life once they are hospitalized. In this review, the authors discuss the history, status, and future of artificial lungs, focusing on long-term artificial respiratory support as a destination therapy. Respiratory assist devices, such as artificial lungs, could eventually become analogous to ventricular assist devices.

KEYWORDS:

artificial lung; destination therapy; extracorporeal membrane oxygenation; heart failure; lung failure; transplantation; ventricular assist device

PMID:
30261966
DOI:
10.1016/j.jacc.2018.07.049

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center